Veterinary Oncology Market Growth Fueled by Canine and Feline Care

Veterinary Oncology Market Size, Key Players with Dynamics and Shares

The veterinary oncology market size recorded US$ 1.58 billion in 2024, set to grow to US$ 1.77 billion in 2025 and projected to hit nearly US$ 4.86 billion by 2034, with a CAGR of 12.14% throughout the forecast timeline.

The global veterinary oncology market is growing significantly, driven by the increasing prevalence of cancer among companion animals, rising pet ownership, and advancements in diagnostic imaging and targeted therapies. The market is projected to surpass USD 5 billion by 2034, expanding from around USD 1.7 billion in 2024. North America dominates the sector due to its advanced veterinary infrastructure and high expenditure on pet healthcare.

Key Takeaways

• Veterinary oncology sector pushed the market to USD 1.58 billion by 2024.
• Long-term projections show USD 4.86 billion valuation by 2034.
• Growth is expected at a steady CAGR of 12.14% in between 2025 to 2034.
• North America dominated the veterinary oncology market with a revenue share of approximately 53.9% in 2024.
• Europe is expected to grow at the fastest CAGR in the market during the forecast Period.
• By animal type, the canine segment held the largest market share of approximately 86.09% in 2024.
• By animal type, the feline segment is expected to grow at the fastest CAGR in the market during the forecast Period.
• By therapy type, the surgery segment dominated the market with the revenue share of approximately 36.09%.
• By therapy type, the chemotherapy segment is expected to grow at the fastest CAGR in the market during the forecast Period.
• By cancer type, the skin cancer segment led the market with the largest revenue share of approximately 39.01% in 2024.
• By cancer type, the lymphoma segment is expected to grow at the fastest CAGR in the market during the forecast Period.

Key Indicators and Highlights

What is the significance of Veterinary Oncology?

The veterinary oncology market is growing due to rising awareness of animal health and increasing availability of advanced cancer treatments for pets. The Market encompasses the diagnosis, treatment, and management of cancers in animals, primarily companion animals such as dogs, cats, and horses. This market includes a range of services and products, from diagnostic imaging and laboratory tests to surgical interventions, chemotherapy, immunotherapy, and radiation therapy.

The growing prevalence of cancer in pets, advancements in veterinary medical technologies, and increasing pet ownership and expenditure on animal healthcare are driving the expansion of the veterinary oncology market. According to the Veterinary Cancer Society, cancer accounts for nearly half of deaths in dogs, especially those above 10 years, and about one-third in cats. Moreover, one in four dogs is likely to develop tumors or abnormal tissue growth during their lifetime.

Veterinary Oncology Market Outlook

• Sustainability Trends: The market embraces sustainability through eco-friendly manufacturing, reduced pharmaceutical waste, ethical sourcing, and energy-efficient veterinary practices, supporting greener healthcare solutions for animal cancer treatment.
• Major Investors: Major investors in the veterinary oncology market include Zoetis, Elanco, Merck Animal Health, Boehringer Ingelheim, Virbac, and Mars Petcare, investing in innovative cancer therapies, advanced diagnostics, and sustainable veterinary care advancements.
• Startup Ecosystem: The veterinary oncology startup ecosystem is expanding, with companies developing advanced diagnostics, personalized cancer therapies, AI-driven treatment platforms, and tele-oncology solutions to enhance early detection and improve animal cancer care.

How Can AI Affect the Market?

AI is poised to transform the veterinary oncology market by improving early cancer detection, enhancing diagnostic accuracy, and enabling personalized treatment plans for pets. Machine learning algorithms can analyze medical imaging and genomic data, helping veterinarians identify tumors faster and predict treatment outcomes more precisely. Additionally, AI-driven platforms streamline research, optimize drug development, and support telemedicine, ultimately increasing efficiency, reducing costs, and improving overall cancer care for companion animals.

What are the Key trends in the Veterinary Oncology Market in 2024?

• Launch of Targeted Therapies and Immunotherapies- New veterinary oncology drugs and treatments, such as targeted chemotherapy agents and immunotherapies, are improving survival rates and driving market growth. Companies like Elanco and Zoetis are actively developing novel therapies.
• In June 2025, ELIAS Animal Health shared interim results from a clinical trial assessing its autologous therapy, ELIAS Cancer Immunotherapy (ECI®), in combination with chemotherapy for treating canine osteosarcoma.
• Advancements in Diagnostic Technologies- Innovations in imaging (CT, MRI, PET scans) and molecular diagnostics allow earlier and more accurate cancer detection in pets. For example, AI-enabled imaging tools now help veterinarians identify tumors faster.
• In September 2024, Boehringer Ingelheim International GmbH acquired Saiba Animal Health AG to expand its animal therapeutics offerings, with Saiba’s advanced vaccine development platform set to boost the veterinary oncology field.

FDA-Approved Drugs for Pets

Segmental Insights

How does the Canine Segment dominate the Veterinary Oncology Market in 2024?

The canine segment dominated the market with the revenue share os approximately 86.09% in 2024 due to a higher prevalence of cancer in dogs compared to other pets. Around 30–40% of dogs develop cancer during their lifetime, with nearly 50% of dogs over 10 years affected. Common cancers include lymphoma, osteosarcoma, and hemangiosarcoma. This high incidence drives greater demand for specialized veterinary oncology services, diagnostics, and treatments, making canines the primary focus for market growth in the animal-type segment.

The feline segment in veterinary oncology is projected to experience a higher compound annual growth rate during the forecast period due to increasing awareness, advancements in diagnostic technologies, and a growing focus on feline-specific treatments. The International Fund for Animal Welfare (IFAW) reports over 220 million pet cats globally, while the American Veterinary Medical Association (AVMA) estimates around 73.8 million pet cats in the U.S. in 2024. The rising incidence and improved detection methods are driving demand for specialized veterinary oncology services tailored for felines.

Why Did the Surgery Segment Dominate the Veterinary Oncology Market in 2024?

The surgery segment dominates the market with the revenue share of approximately 36.09% due to its effectiveness in treating various cancers, especially solid tumors in companion animals. Surgical procedures allow for immediate tumor removal, often improving survival rates and quality of life. In 2024, surgery accounted for a significant portion of revenue within therapy types, reflecting widespread adoption in veterinary practices. Its pivotal role in cancer management, combined with advancements in surgical techniques and post-operative care, continues to drive market preference and growth.

The chemotherapy segment in veterinary oncology is anticipated to experience a higher compound annual growth rate during the forecast period due to advancements in drug formulations, improved delivery methods, and increased adoption of combination therapies. These innovations enhance the effectiveness and safety of chemotherapy treatments for companion animals. As a result, veterinary clinics are expanding their oncology services, leading to a greater market share for chemotherapy-based therapies in the veterinary oncology sector.

What made the Skin Cancer Segment Dominant in the Veterinary Oncology Market in 2024?

In 2024, the skin cancer segment led the market with the revenue share of approximately 39.01 % due to the high prevalence of skin tumors in dogs.  A study published in PubMed Central in April 2023 reported that 56% of malignant tumors in dogs occurred in the skin, while 69% of benign tumors were also skin-related, highlighting the high prevalence of skin cancers in canines. The skin tumors in dogs are benign, but a significant portion are malignant, including mast cell tumors and melanomas. These tumors often require surgical intervention, and in some cases, additional treatments like chemotherapy or radiation. The widespread occurrence and treatment needs of skin cancers contribute to their dominant market share.

The lymphoma segment in veterinary oncology is projected to grow at the fastest CAGR during the forecast period due to its high prevalence and advancements in treatment options. Canine lymphoma, particularly multicentric lymphoma, is among the most common hematologic cancers in dogs, with an incidence rate of approximately 20–107 cases per 100,000 dogs. According to a July 2024 MDPI article, pulmonary carcinoma is the most common form of primary lung cancer in dogs, with pulmonary adenocarcinoma being the predominant subtype, representing 60–80% of cases. The availability of targeted therapies and improved diagnostic techniques are expected to drive market expansion in this segment.

Regional Insights

How is North America contributing to the Expansion of the Veterinary Oncology Market?

North America led the market with the revenue share of approximately 53.9 % in 2024, driven by a high pet ownership rate and advanced healthcare infrastructure. The U.S. alone had an estimated 73.8 million pet cats in 2024, contributing to a significant demand for veterinary services. Additionally, the region's well-established veterinary workforce, with over 73,000 veterinary assistants and laboratory animal caretakers, supports the growth of specialized oncology services. These factors collectively positioned North America as the dominant market in veterinary oncology.

Which Initiatives taken by U.S. in the Veterinary Oncology Market?

In 2024, the U.S. government implemented several initiatives to advance veterinary oncology. The National Institutes of Health (NIH) launched the Animal and Veterinary Innovation Centers (U18) program to foster long-term partnerships addressing critical animal health issues, including cancer research. Additionally, the National Cancer Institute (NCI) announced funding opportunities to enhance mammalian cancer models, aiming to improve translational research and patient outcomes. These efforts reflect a commitment to advancing veterinary oncology through collaborative research and innovation.

How Canada is Approaching the Veterinary Oncology Market?

Canada is actively advancing veterinary oncology through several initiatives. The Canadian Veterinary Medical Association (CVMA) established the Pharmaceutical Access Advisory Committee (PAAC) in October 2024 to address drug shortages and improve access to essential veterinary health products, including oncology treatments.  Additionally, the CVMA offers wellness programs like "The Working Mind" to support mental health among veterinary professionals, ensuring a resilient workforce capable of delivering quality cancer care for animals.

How is Europe Accelerating the Veterinary Oncology Market?

Europe is accelerating its market through strategic initiatives and regulatory advancements. The European Commission's proposed pharmaceutical legislation aims to streamline regulatory processes, enhancing the development and approval of veterinary oncology treatments. Additionally, the European Union's Mission on Cancer emphasizes improving the quality of life for cancer patients, including animals, which supports the integration of veterinary oncology into broader cancer care strategies. These efforts collectively foster innovation and accessibility in veterinary oncology across Europe.

Veterinary Oncology Market Value Chain Analysis

• Regulatory Approvals-Regulatory approvals for veterinary oncology are overseen by regional bodies such as the U.S. FDA and the European Medicines Agency (EMA). Because of the smaller and specialized market, veterinary drugs often use more flexible approval pathways, including conditional approvals, enabling earlier access to the market compared to human medicines.
• Packaging and Serialization- Packaging and serialization in veterinary oncology are vital for maintaining drug safety, effectiveness, and compliance with regulations. Strong track-and-trace systems are essential to prevent counterfeit medications and protect the animal healthcare supply chain.
• Formulation and Final Dosage Preparation- In veterinary oncology, chemotherapy formulations and dosages must be carefully calculated and compounded to ensure safety for staff, pet owners, and patients. Cytotoxic drugs can be administered intravenously, subcutaneously, intramuscularly, intralesionally, or orally, with oral medications often requiring special compounding.

Top Vendors and their Offerings

• Zoetis Inc.- Zoetis Inc. is a global animal health company offering veterinary oncology products like Palladia® for canine tumors, monoclonal antibody therapies, and advanced diagnostic tools for cancer detection and monitoring.
• Elanco- Elanco Inc. offers Tanovea® (rabacfosadine for injection), the first and only FDA-approved treatment for canine lymphoma, providing a novel approach to managing this common cancer in dogs.
• IDEXX Laboratories- IDEXX Laboratories provides veterinary oncology solutions, including IDEXX Cancer Dx™ for early lymphoma detection, Nu. Q Vet Cancer Test for multiple canine cancers, and inVue Dx™ AI-powered cytology for faster, accurate diagnostics.
• VetDC Inc.- VetDC Inc. develops innovative cancer therapies for pets, including Tanovea®, the first FDA-approved chemotherapy for canine lymphoma, offering effective, less intensive treatment with high response rates and improved progression-free survival.
• Anivive Lifesciences- Anivive Lifesciences develops veterinary oncology therapies and diagnostics, including investigational drugs for canine hemangiosarcoma and osteosarcoma, plus SearchLight DNA™ tumor genotyping, providing AI-driven, personalized cancer treatment for pets.

Top Companies in the Veterinary Oncology Market

• Boehringer Ingelheim International GmbH
• Siemens Healthineers (Varian)
• Accuray Incorporated
• PetCure Oncology
• Nippon Zenyaku Kogyo (ZENOAQ)
• Morphogenesis Inc.
• Karyopharm Therapeutics
• Regeneus Ltd
• OHC (The One Health Company)
• LiteCure LLC
• Cutting Edge Laser Technologies
• Aesculight LLC
• Mars Petcare
• Virbac
• Merck & Co., Inc.

Recent Developments in the Veterinary Oncology Market

• In March 2025, Privo Technologies Inc. launched BeneVet Oncology, a new platform aimed at improving companion animal health by utilizing Privo’s unique drug delivery technologies to address unmet veterinary medical needs.
• In January 2025, IDEXX Laboratories launched IDEXX Cancer Dx, the first residual diagnostic panel for early lymphoma detection in dogs, targeting the 20 million North American dogs at elevated cancer risk.

Segments Covered in the Report

By Animal Type

• Canine
• Feline
• Equine: ~ 1.53%.

By Therapy Type

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others: Including targeted therapies and gene therapies.

By Cancer Type

• Skin Cancer
• Lymphoma
• Mast Cell Tumors
• Osteosarcoma
• Others: Including mammary tumors, hemangiosarcoma, and soft tissue sarcomas.

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait